Literature DB >> 8013374

Cloning of a complementary deoxyribonucleic acid encoding the murine homolog of the very low density lipoprotein/apolipoprotein-E receptor: expression pattern and assignment of the gene to mouse chromosome 19.

M E Gåfvels1, L G Paavola, C O Boyd, P M Nolan, F Wittmaack, A Chawla, M A Lazar, M Bucan, B O Angelin, J F Strauss.   

Abstract

We report the cloning of a complementary DNA for the mouse homolog of the very low density lipoprotein (VLDL)/apolipoprotein-E receptor (VLDLR), the deduced amino acid sequence of the protein, and the mapping of the gene encoding the receptor to mouse chromosome 19. Northern hybridization revealed that the VLDLR messenger RNA (mRNA) is most abundant in skeletal muscle, heart, kidney, and brain. It was also detected in lung and in low levels in liver, but it was not found in spleen or testes. Levels of VLDLR mRNA in mouse placenta increased from days 8-18 of gestation. The VLDLR mRNA was induced in 3T3-L1 cells undergoing differentiation into adipocytes. The increase in VLDLR mRNA paralleled the rise in lipoprotein lipase and hormone-sensitive lipase mRNAs. However, VLDLR and low density lipoprotein receptor-related protein were increased in the presence of retinoic acid, whereas the induction of lipoprotein lipase and hormone-sensitive lipase mRNAs was inhibited. Our observations demonstrate regulated expression of the VLDLR gene in placenta and adipocytes, where the receptor protein may play roles in the uptake of triglyceride-rich particles for storage of lipid (adipocytes) or for lipid transport to the fetus (placenta). The availability of a murine complementary DNA probe and the knowledge of the map position of the VLDLR gene in the mouse genome will facilitate studies on the function and regulation of this protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013374     DOI: 10.1210/endo.135.1.8013374

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.

Authors:  Mali Liu; Guoxin Wu; Jennifer Baysarowich; Michael Kavana; George H Addona; Kathleen K Bierilo; John S Mudgett; Guillaume Pavlovic; Ayesha Sitlani; John J Renger; Brian K Hubbard; Timothy S Fisher; Celina V Zerbinatti
Journal:  J Lipid Res       Date:  2010-05-07       Impact factor: 5.922

2.  Effective generation of very low density lipoprotein receptor transgenic mice by overlapping genomic DNA fragments: high testis expression and disturbed spermatogenesis.

Authors:  P J Tacken; A van der Zee; T L Beumer; R J Florijn; M J Gijpels; L M Havekes; R R Frants; K W van Dijk; M H Hofker
Journal:  Transgenic Res       Date:  2001-06       Impact factor: 2.788

3.  The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.

Authors:  K M Argraves; K F Kozarsky; J T Fallon; P C Harpel; D K Strickland
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

4.  Chiloscyllium plagiosum low-density lipoprotein receptor: evolutionary conservation of five different functional domains.

Authors:  K D Mehta; R Chang; J Norman
Journal:  J Mol Evol       Date:  1996-02       Impact factor: 2.395

5.  Expression of very low density lipoprotein receptor in the vascular wall. Analysis of human tissues by in situ hybridization and immunohistochemistry.

Authors:  H A Multhaupt; M E Gåfvels; K Kariko; H Jin; C Arenas-Elliot; B I Goldman; J F Strauss; B Angelin; M J Warhol; K R McCrae
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

6.  Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.

Authors:  Takeshi Takazawa; Toshimasa Yamauchi; Atsushi Tsuchida; Makoto Takata; Yusuke Hada; Masato Iwabu; Miki Okada-Iwabu; Kohjiro Ueki; Takashi Kadowaki
Journal:  J Biol Chem       Date:  2009-08-25       Impact factor: 5.157

7.  A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins.

Authors:  Keiko Sakai; Oliver Tiebel; M Cecilia Ljungberg; Merry Sullivan; Hye-Jeong Lee; Tomoya Terashima; Rongying Li; Kunihisa Kobayashi; Hui-Chen Lu; Lawrence Chan; Kazuhiro Oka
Journal:  Brain Res       Date:  2009-04-22       Impact factor: 3.252

8.  Mutant oocytic low density lipoprotein receptor gene family member causes atherosclerosis and female sterility.

Authors:  H Bujo; T Yamamoto; K Hayashi; M Hermann; J Nimpf; W J Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

9.  KIT is required for hepatic function during mouse post-natal development.

Authors:  Laetitia Magnol; Marie-Clémence Chevallier; Valérie Nalesso; Stéphanie Retif; Helmut Fuchs; Martina Klempt; Patricia Pereira; Michel Riottot; Sandra Andrzejewski; Bich-Thuy Doan; Jean-Jacques Panthier; Anne Puech; Jean-Claude Beloeil; Martin Hrabe de Angelis; Yann Hérault
Journal:  BMC Dev Biol       Date:  2007-07-05       Impact factor: 1.978

Review 10.  Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.

Authors:  Nicola Ferri
Journal:  Scientifica (Cairo)       Date:  2012-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.